Comparative genomic profiling of glandular bladder tumours.
Adenocarcinoma
/ pathology
Adult
Aged
Aged, 80 and over
B7-H1 Antigen
/ analysis
Biomarkers, Tumor
/ analysis
Female
Genomics
/ methods
Humans
Male
Middle Aged
Mutation
Neoplasms, Glandular and Epithelial
/ genetics
Urinary Bladder
/ pathology
Urinary Bladder Neoplasms
/ genetics
Urothelium
/ pathology
Bladder adenocarcinoma
Molecular genetics
Urachal carcinoma
Urothelial carcinoma
Urothelial carcinoma with glandular differentiation
Journal
Virchows Archiv : an international journal of pathology
ISSN: 1432-2307
Titre abrégé: Virchows Arch
Pays: Germany
ID NLM: 9423843
Informations de publication
Date de publication:
Sep 2020
Sep 2020
Historique:
received:
10
12
2019
accepted:
27
02
2020
revised:
19
02
2020
pubmed:
22
3
2020
medline:
17
9
2020
entrez:
22
3
2020
Statut:
ppublish
Résumé
Primary glandular bladder tumours (bladder adenocarcinoma [BAC], urachal adenocarcinoma [UAC], urothelial carcinoma with glandular differentiation [UCg]) are rare malignancies with histological resemblance to colorectal adenocarcinoma (CORAD) in the majority of this subgroup. Definite case numbers are very low, molecular data are limited and the pathogenesis remains poorly understood. Therefore, this study was designed to complement current knowledge by in depth analysis of BAC (n = 12), UAC (n = 13), UCg (n = 11) and non-invasive glandular lesions (n = 19). In BAC, in addition to known alterations in TP53, Wnt, MAP kinase and MTOR pathway, mutations in SMAD4, ARID1A and BRAF were identified. Compared to published data on muscle invasive bladder cancer (BLCA) and CORAD, UCg exhibited frequent "urothelial" like alterations while BAC and UAC were characterised by a more "colorectal" like mutational pattern. Immunohistochemically, there was no evidence of DNA mismatch repair deficiency or PD-L1 tumour cell positivity in any sample. Depending on the used antibody 0-45% of BAC, 0-30% of UCg and 0% UAC cases exhibited PD-L1 expressing tumour associated immune cells. A single BAC (9%, 1/11) showed evidence of ARID1A protein loss, and two cases of UCg (20%, 2/10) showed loss of SMARCA1 and PBRM1, respectively. Taken together, our data suggest at least in part involvement of similar pathways driving tumourigenesis of adenocarcinomas like BAC, UAC and CORAD independent of their tissue origin. Alterations of TERT and FBXW7 in single cases of intestinal metaplasia further point towards a possible precancerous character in line with previous reports.
Identifiants
pubmed: 32198650
doi: 10.1007/s00428-020-02787-8
pii: 10.1007/s00428-020-02787-8
pmc: PMC7443184
doi:
Substances chimiques
B7-H1 Antigen
0
Biomarkers, Tumor
0
CD274 protein, human
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
445-454Subventions
Organisme : Medizinische Fakultät, RWTH Aachen University
ID : 42/13
Références
J Med Genet. 2017 Aug;54(8):572-578
pubmed: 28348108
Urol Oncol. 2015 Jan;33(1):21.e1-21.e9
pubmed: 25465301
Eur Urol. 2014 Feb;65(2):367-9
pubmed: 24035680
PLoS One. 2014 Sep 05;9(9):e107027
pubmed: 25191845
Mol Cancer Ther. 2018 Jan;17(1):3-16
pubmed: 29295962
Cancer Discov. 2016 Jul;6(7):714-26
pubmed: 27147599
Urol Ann. 2015 Apr-Jun;7(2):177-82
pubmed: 25838209
Hum Pathol. 2014 Feb;45(2):327-30
pubmed: 24355196
Clin Cancer Res. 2005 Nov 1;11(21):7743-8
pubmed: 16278395
Mod Pathol. 2017 Aug;30(8):1133-1143
pubmed: 28548125
PLoS Genet. 2017 Aug 7;13(8):e1006938
pubmed: 28787442
Hum Pathol. 2019 Dec;94:58-63
pubmed: 31666198
Arch Pathol Lab Med. 2018 Oct;142(10):1164-1176
pubmed: 30281367
Hum Pathol. 2016 Jul;53:8-13
pubmed: 26980028
J Exp Med. 2007 Aug 6;204(8):1813-24
pubmed: 17646409
Eur J Cancer. 2019 Jan;106:234-243
pubmed: 30528808
Ann Oncol. 2017 Feb 1;28(2):254-269
pubmed: 28426098
JCO Precis Oncol. 2017;2017:
pubmed: 29850653
J Clin Pathol. 2016 Apr;69(4):307-12
pubmed: 26463756
Eur Urol. 2016 Nov;70(5):771-775
pubmed: 27178450
JCO Precis Oncol. 2017 Jul 06;1:
pubmed: 32913973
Oncotarget. 2016 May 17;7(20):29211-5
pubmed: 27078850
Clin Cancer Res. 2007 Oct 15;13(20):6232-6
pubmed: 17947491
Virchows Arch. 2019 Jan;474(1):13-20
pubmed: 30302546
Histopathology. 2012 Dec;61(6):1036-42
pubmed: 22804747
Int J Biol Sci. 2018 Jan 12;14(2):111-123
pubmed: 29483830
Oncotarget. 2016 Jun 28;7(26):39293-39301
pubmed: 27283768
Nature. 2014 Mar 20;507(7492):315-22
pubmed: 24476821
Cancer Discov. 2012 May;2(5):401-4
pubmed: 22588877
Nat Rev Cancer. 2008 Feb;8(2):83-93
pubmed: 18094723
Ann Diagn Pathol. 2015 Oct;19(5):301-5
pubmed: 26239299
Cell. 2017 Oct 19;171(3):540-556.e25
pubmed: 28988769
Pathobiology. 2015;82(2):53-7
pubmed: 25997473
Pathol Int. 2017 Dec;67(12):597-601
pubmed: 29047227
Am J Surg Pathol. 1996 Dec;20(12):1462-8
pubmed: 8944039
Nat Genet. 2013 Oct;45(10):1113-20
pubmed: 24071849
Nature. 2012 Jul 18;487(7407):330-7
pubmed: 22810696
Clin Cancer Res. 2019 Mar 15;25(6):1948-1956
pubmed: 30587545
Mod Pathol. 2014 Jan;27(1):107-12
pubmed: 23887300
Urology. 2008 May;71(5):915-8
pubmed: 18455631
Sci Signal. 2013 Apr 02;6(269):pl1
pubmed: 23550210
Int J Cancer. 2018 Oct 1;143(7):1764-1773
pubmed: 29672836